ABCL AbCellera Biologics Inc
Price (delayed)
$2.09
Market cap
$622.79M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.55
Enterprise value
$502.21M
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners
Highlights
The company's quick ratio rose by 30% YoY
AbCellera Biologics's debt has decreased by 15% YoY and by 8% from the previous quarter
AbCellera Biologics's net income has decreased by 11% YoY but it has increased by 7% from the previous quarter
ABCL's EPS is up by 10% from the previous quarter but it is down by 8% YoY
The company's revenue fell by 24% YoY and by 13% QoQ
The gross profit has contracted by 24% YoY and by 13% from the previous quarter
Key stats
What are the main financial stats of ABCL
Market
Valuations
Earnings
Shares outstanding
297.99M
Market cap
$622.79M
Enterprise value
$502.21M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.58
Price to sales (P/S)
21.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
17.42
Revenue
$28.83M
Gross profit
$28.83M
Operating income
-$314.77M
Net income
-$162.86M
EBIT
-$200.4M
EBITDA
-$103.4M
Free cash flow
-$186.95M
Per share
Balance sheet
Liquidity
EPS
-$0.55
EPS diluted
-$0.55
Free cash flow per share
-$0.64
Book value per share
$3.58
Revenue per share
$0.1
TBVPS
$4.32
Total assets
$1.36B
Total liabilities
$304.47M
Debt
$60.74M
Equity
$1.06B
Working capital
$674.76M
Debt to equity
0.06
Current ratio
9.81
Quick ratio
8.93
Net debt/EBITDA
1.17
Margins
Efficiency
Dividend
EBITDA margin
-358.6%
Gross margin
100%
Net margin
-564.8%
Operating margin
-1,091.7%
Return on assets
-11.6%
Return on equity
-14.9%
Return on invested capital
-18.2%
Return on capital employed
-15.6%
Return on sales
-695%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ABCL stock price
How has the AbCellera Biologics stock price performed over time
Intraday
-6.28%
1 week
-17.39%
1 month
-19.15%
1 year
-52.93%
YTD
-28.67%
QTD
-6.28%
Financial performance
How have AbCellera Biologics's revenue and profit performed over time
Revenue
$28.83M
Gross profit
$28.83M
Operating income
-$314.77M
Net income
-$162.86M
Gross margin
100%
Net margin
-564.8%
AbCellera Biologics's operating margin has shrunk by 75% YoY and by 17% QoQ
AbCellera Biologics's net margin has decreased by 47% YoY and by 6% from the previous quarter
ABCL's operating income is down by 33% year-on-year and by 2.2% since the previous quarter
The company's revenue fell by 24% YoY and by 13% QoQ
Growth
What is AbCellera Biologics's growth rate over time
Valuation
What is AbCellera Biologics stock price valuation
P/E
N/A
P/B
0.58
P/S
21.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
17.42
ABCL's EPS is up by 10% from the previous quarter but it is down by 8% YoY
ABCL's P/B is 82% below its 5-year quarterly average of 3.4 and 31% below its last 4 quarters average of 0.9
The equity has declined by 8% year-on-year and by 2% since the previous quarter
The company's revenue fell by 24% YoY and by 13% QoQ
The P/S is 22% less than the last 4 quarters average of 29.1 but 21% more than the 5-year quarterly average of 18.8
Efficiency
How efficient is AbCellera Biologics business performance
ABCL's ROS has plunged by 52% YoY and by 13% from the previous quarter
AbCellera Biologics's ROE has decreased by 20% YoY but it has increased by 5% from the previous quarter
The ROA has contracted by 20% YoY but it has grown by 4.9% from the previous quarter
The company's return on invested capital fell by 16% YoY
Dividends
What is ABCL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ABCL.
Financial health
How did AbCellera Biologics financials performed over time
ABCL's current ratio is up by 34% YoY and by 5% QoQ
The company's quick ratio rose by 30% YoY
AbCellera Biologics's debt is 94% less than its equity
AbCellera Biologics's debt has decreased by 15% YoY and by 8% from the previous quarter
The equity has declined by 8% year-on-year and by 2% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.